Equities

Amylyx Pharmaceuticals Inc

AMLX:NSQ

Amylyx Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.88
  • Today's Change-0.04 / -1.37%
  • Shares traded1.48m
  • 1 Year change-84.60%
  • Beta--
Data delayed at least 15 minutes, as of Sep 18 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company’s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The Company’s Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia.

  • Revenue in USD (TTM)298.76m
  • Net income in USD-165.87m
  • Incorporated2014
  • Employees384.00
  • Location
    Amylyx Pharmaceuticals Inc43 THORNDIKE STREETCAMBRIDGE 02141United StatesUSA
  • Phone+1 (617) 682-0917
  • Fax+1 (302) 636-5454
  • Websitehttps://www.amylyx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Global Pharmatech Inc.3.18m-2.24m138.32m217.00--1.02--43.51-0.0964-0.09640.13670.34280.22921.593.5714,649.77-16.44---22.55--46.21---71.75--1.62-9.870.2223--32.43---142.03------
Elutia Inc24.99m-70.10m139.99m54.00------5.60-3.05-2.861.12-2.280.53032.325.08462,722.20-148.77-42.93-1,212.93-79.3442.4643.32-280.53-64.160.6842-0.6561-----49.69-8.71-25.39--12.74--
Hongchang International Co Ltd4.65m-292.22k140.08m8.00--3.57--30.13-0.0006-0.00060.00930.07570.16475.028.74---0.8827-7.98-0.9331-10.943.9211.47-5.36-64.883.77--0.2642--3,289.22---42.63------
Eton Pharmaceuticals Inc31.38m-6.69m147.78m30.00--10.94--4.71-0.2596-0.25961.220.52291.008.827.891,046,033.00-21.31-46.22-38.27-58.2059.4872.16-21.31-76.861.28--0.2571--48.90--89.62--26.85--
Biostem Technologies Inc131.44m7.87m155.99m67.0028.628.6119.301.190.33460.33467.311.112.807.413.35--16.78--107.11--94.73--5.98--1.2015.520.2012--------------
Lifecore Biomedical Inc128.26m9.33m156.81m524.0034.2513.718.621.220.14820.23183.831.760.50552.144.26244,774.803.68-5.914.35-8.3332.6331.017.27-19.161.060.23730.6923--24.20-25.46114.5334.47-16.72--
Telomir Pharmaceuticals Inc0.00-18.74m165.82m1.00--105.78-----0.6855-0.68550.000.05290.00----0.00-467.16---686.91-------------0.92990.00-------1,430.39------
ASP Isotopes Inc2.30m-27.05m176.72m76.00--12.55--76.98-0.628-0.6280.05490.21120.068----30,206.32-71.81---89.44--36.54---1,055.85-----8.110.6748-------229.34------
Greenwich Lifesciences Inc0.00-10.22m190.07m3.00--32.16-----0.7942-0.79420.000.44960.00----0.00-112.41-36.43-123.67-38.31------------0.00-------13.63------
Amylyx Pharmaceuticals Inc298.76m-165.87m198.80m384.00--0.7608--0.6654-2.45-2.454.343.840.76053.6915.91778,026.10-42.22---50.91--84.64---55.52--4.66--0.00--1,612.94--124.84------
Scilex Holding Co50.83m-171.53m199.46m113.00------3.92-1.40-1.400.4425-1.770.44015.221.55484,123.80-102.93------68.24---233.88--0.1853-3.72----22.90---614.67------
Mediwound Ltd20.14m-19.97m199.87m100.00--9.63--9.92-2.16-2.162.181.920.33115.536.55201,410.00-32.83-24.48-49.28-32.9213.2543.27-99.17-38.431.51-3.260.2623---29.4840.6065.73--64.66--
Procaps Group SA414.10m52.20m209.81m5.50k3.575.333.010.50670.52090.52094.160.34910.8541.873.3875,290.1810.77--19.01--55.04--12.61--0.9861--0.8829--0.0434--142.18------
Rigel Pharmaceuticals Inc130.30m-14.23m240.70m147.00------1.85-0.8136-0.81367.45-1.701.061.055.24886,401.40-11.59-28.82-19.93-47.2692.4197.88-10.92-35.761.48-1.732.00---2.7921.3057.16--68.45--
Inhibrx Biosciences Inc1.85m1.63bn249.28m166.000.14211.140.1523134.53121.21121.210.043415.150.0079--4.8611,162.65693.63-77.06815.31-93.91----88,264.55-1,590.91---21.960.00---17.88-26.85-66.20--26.30--
Data as of Sep 18 2024. Currency figures normalised to Amylyx Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

29.83%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 20244.20m6.17%
AQR Capital Management LLCas of 30 Jun 20243.34m4.91%
BlackRock Fund Advisorsas of 30 Jun 20242.05m3.01%
Almitas Capital LLCas of 30 Jun 20241.90m2.80%
Alyeska Investment Group LPas of 30 Jun 20241.82m2.68%
Millennium Management LLCas of 30 Jun 20241.54m2.26%
683 Capital Management LLCas of 30 Jun 20241.50m2.21%
Goldman Sachs Asset Management LPas of 30 Jun 20241.34m1.96%
Citadel Advisors LLCas of 30 Jun 20241.31m1.92%
D. E. Shaw & Co. LPas of 30 Jun 20241.31m1.92%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.